Zonegran Russian approval prompts Eisai's expansion in that market
Eisai (TYO: 4523), a leading Japanese drugmaker, says it plans to expand its operations into Russia, with the approval of its first product in this market - the epilepsy treatment, Zonegran (zonisamide).
Eisai’s entry into the Russian health care marketplace is part of the company’s plan (HAYABUSA) to have a presence in the top 20 pharmaceutical market regions and make contributions to more than 500 million patients by 2015. The Russian pharmaceuticals market constitutes the 11th largest in the world and is expected to see high growth going forward.
To be available this fiscal year
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze